Skip to content

Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)

Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01082393
Acronym
Koebner
Enrollment
14
Registered
2010-03-08
Start date
2010-02-16
Completion date
2015-12-01
Last updated
2022-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Keywords

vitiligo

Brief summary

We will investigate the process of vitiligo induction and the influence of different commonly used cream treatments on this process. Studies comparing different treatments for vitiligo in the induction stage of the disease are still missing. The study hypothesis = cream treatment can stop actively spreading vitiligo lesions during the early induction stage of the disease.

Interventions

DRUGtopical tacrolimus treatment

4 applications (day 1,day 3, day 6 and day10)

DRUGtopical pimecrolimus treatment

4 applications (day 1, day 3, day 6 and day 10)

DRUGlocal mometasone furoate treatment

4 applications (day 1, day 3, day 6 and day 10)

4 applications (day 1, day 3, day 6 and day 10)

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Male and female, * Age 18-70 years, * Extensive vitiligo (\> 50% body surface area), * Patients asking for depigmenting therapy, * Not pregnant.

Exclusion criteria

* Children, * Non extensive vitiligo (\< 50% boy surface area), * Patients not asking for depigmenting therapies, * Pregnant.

Design outcomes

Primary

MeasureTime frameDescription
percentage of skin pigmentation in the treated areaafter 1 day, 10 days, 30 days and 60 daysdigital image analysis system for surface measurement

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026